Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to -$35.1 million.

  • Viridian Therapeutics, Inc.\DE's Net Income towards Common Stockholders rose 5417.68% to -$35.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.5 million, marking a year-over-year decrease of 1774.81%. This contributed to the annual value of -$269.9 million for FY2024, which is 1355.09% down from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Net Income towards Common Stockholders of -$35.1 million as of Q3 2025, which was up 5417.68% from -$100.7 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Net Income towards Common Stockholders ranged from a high of -$14.0 million in Q3 2021 and a low of -$100.7 million during Q2 2025
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$47.7 million (2023), whereas its average is -$49.4 million.
  • The largest annual percentage gain for Viridian Therapeutics, Inc.\DE's Net Income towards Common Stockholders in the last 5 years was 6810.08% (2021), contrasted with its biggest fall of 17916.08% (2021).
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Net Income towards Common Stockholders (Quarter) stood at -$28.9 million in 2021, then crashed by 58.17% to -$45.8 million in 2022, then tumbled by 46.03% to -$66.9 million in 2023, then decreased by 19.33% to -$79.8 million in 2024, then surged by 56.07% to -$35.1 million in 2025.
  • Its last three reported values are -$35.1 million in Q3 2025, -$100.7 million for Q2 2025, and -$86.9 million during Q1 2025.